EBS PHARMA
ActiveSummary
EBS PHARMA has been active since 2018 and the Belgian Official Gazette contains no insolvency or warning signals. The 2025 annual accounts show equity of €20,714 and a net result of €22,677. Equity remains stable across the filed financial years (±1.2% per year). Its solvency ranks better than 46% of 1,867 sector peers (NACE 10, financial year 2025). The computed 12-month bankruptcy probability is 0.3% (very low).
History
Acts, filings and financial milestones
01-10
Gazette deed
Resignation: Tri-Sana (director)Declaration · Shareholding4 facts ▸
- General meeting, 01-09-2026
- Director resignation, Tri-Sana (director)
- Declaration, “verklaring van eenhoofdigheid, neergelegd in het vennootschapsdossier ter griffie van de Ondernemingsrechtbank” (deed in Dutch)
- Shareholding, 01-09-2026
About the unread acts
Of the 3 Belgian Official Gazette deeds we know for this company, 1 has been read. The other 2 have not been read yet: what they contain is neither established nor disproved here.